

AccuBoost® Booster Club

Notes from the editor:

This issue covers the launch of the AccuLoader HDR offering as part of a super-turnkey system which makes one-stop shopping for AccuBoost a reality, coverage in the news, the first of a series of symposia/roadshows in collaboration with Varian Brachytherapy Group, the announcement of the upcoming workshop in collaboration with Elekta and details of exhibiting at this year's ASTRO.

The highlight of this issue is the summary of the AccuBoost "patient data registry" article that finally appeared in the August issue of the Red Journal (IJROBP). The coverage includes updates on this subject from the oral presentation at this year's World Congress in Barcelona.

Inside this issue:

- First AccuBoost symposium2
- Upcoming AccuBoost workshop2
- AccuBoost at ASTRO3
- AccuBoost's "patient data registry" publication 3-4

 Find us on Facebook

 @AccuBoost

AccuBoost super-turnkey offering

"If you build it, they will come." This popular belief contemplates that it is worth being pro-active in anticipation of a market opportunity. However, for the decision to offer the AccuLoader, the HDR component for AccuBoost, there was no need to be proactive. In reality, we had learned from the potential customers over the years, that they are often ready to offer the AccuBoost treatment option, but lack the prerequisite HDR and left us with the clear message **"just build it."**

The offering of a basic and stripped down AccuLoader HDR, dedicated for AccuBoost, is primarily targeted for radiation oncology facilities that have looked at acquiring HDR independently to deliver the AccuBoost treatment, but have not been able to allocate the capital outlay and could not justify the cost for source changes.

The one-step, one-stop shopping for AccuLoader HDR for AccuBoost, enables the customer to acquire everything that they need to deliver the treatment and nothing that they don't need.

It minimizes the paperwork and eliminates the need for a middleman.

In keeping up with the philosophy of no up-front payment, the AccuLoader HDR is provided with low, fixed monthly payments that are easily compensated by the revenue stream from patient treatment. Service, maintenance and six source changes are included in

the package and paid for throughout the first year of operation. The more frequent source changes keeps the Ir-192 activity at high levels, reduces treatment time and increases efficiency.




acculoader
expanding the horizon of accuboost

5 good reasons for choosing AccuLoader HDR for AccuBoost:

- 1 One-Stop, One Step Shopping
- 2 Simple Configuration Streamlined For Accuboost
- 3 Low, Fixed Monthly Payments
- 4 No Capital Expense
- 5 Six Source Changes Per Year

AccuBoost for APBI in the news

TV coverage for AccuBoost, as an APBI monotherapy, originally aired on WJAR, Channel 10 in the Providence, RI market, was then rebroadcasted on the "Healthcare Watch" program across the nation. The segment was aired in over 30 stations across the nation from Panama City, FL to Kansas City, MO and from Augusta, GA to Altoona, PA. The rescreening of the program created interest on the part of patients with frequent visits to the AccuBoost website, and numerous inquiries, as to the location of the closest treatment facility.



Dr. J. Hepel, the PI of the APBI study, interviewed on Rhode Island Channel 10 News.

Visit us
at booth
#3055 at
the 54th
Annual
ASTRO
Meeting
in Boston
this
October

ASTRO

First AccuBoost symposium

AccuBoost, in collaboration with Varian Brachytherapy, is planning a series of road shows in selected metropolitan areas. The motivation of the roadshow is to provide a forum for radiation oncologists and medical physicists to participate in “peer-to-peer” exchanges related to the details of the procedure. It allows new or pending users of AccuBoost to listen and learn from the experience of some of the more experienced users.


The first in a series of these symposia was held at the Renaissance Hotel in Boca Raton, FL on Sept 22. David Wazer M.D., Chair of the

Dept. of Radiation Oncology at Tufts Medical Center and Rhode Island Hospital, was the speaker at this session that was attended by some 30 radiation oncologists, medical physicists, dosimetrists and therapists – primarily from the greater Miami area. The 90 minute presentation accompanied with a brunch, was followed with a Q & A period.

Based on the success of the first session, a minimum of four additional road shows are being planned for the coming year. The schedule and the list of speakers for the future symposia will be announced soon.

Varian BrachyTherapy 2012 Clinical Forum

Boca Raton
Saturday, September 22, 2012



South Florida Learning Symposium on Technological Updates on APBI & Boost Radiotherapy

VARIAN
medical systems

Upcoming AccuBoost workshop

The second AccuBoost workshop, in collaboration with Nucletron/Elekta is scheduled for November 29-30 at the Lynn Cancer Institute in Boca Raton, FL. The two-day workshop is primarily for the benefit of existing, new or pending users. It provides an opportunity to witness a few live procedures, including patient positioning and treatment along with observation of the work flow for the AccuBoost procedure. It allows for current users to observe “best-of-practice” methods from established sites to improve their skills and efficiency. For the new or pending users, the workshop additionally serves as a substitute for a “site visit”, common in radiation oncology practices.

The workshop will be conducted by radiation oncologists David Wazer, Rashmi Benda, and medical physicist,



The Lynn Cancer Institute in Boca Raton, FL.

Zoubir Ouhib. The clinical features and the physics of AccuBoost will be presented at the two-day workshop. Patient selection, target identification, scheduling and inclusion/exclusion criteria are extensively covered in the sessions.

Nucletron
AN ELEKTA COMPANY

AccuBoost at ASTRO

AccuBoost will be participating in the 54th annual meeting of ASTRO in Boston, October 28 – 31. In addition to exhibiting the latest system, AccuBoost will conduct a number of live presentations from the booth. The schedule for the presentations appears below.

The AccuBoost Appreciation Dinner for this year will be held on Monday, October 29th. This by-invitation-only social gathering provides a unique forum for present and pending AccuBoost users to meet and exchange ideas and share their experiences.

In-booth presentation schedule

Date	Time	Presenter	Title
Sunday, October 28	1:00 PM	David Wazer, MD	What I like about AccuBoost
Sunday, October 28	3:00 PM	Scot Ackerman, MD	Lessons learned: my first 200 patients
Monday October 29	1:00 PM	Anand Kuruvilla, MD	AccuBoost experience: in a community facility
Monday October 29	3:00 PM	Scot Ackerman, MD	AccuBoost: patient selection and work flow
Tuesday October 30	12:00 PM	Yun Yang, PhD	Physics of AccuBoost: new applicators

AccuBoost's "patient data registry" publication

The much awaited publication that summarizes the results of "patient data registry" for AccuBoost, finally appeared in the August 1 issue of the Red Journal (IJROBP). The title page of the registry, reproduced on the right, identifies the AccuBoost procedure as "Noninvasive breast brachytherapy, NIBB". The list of authors, a collection of "who's who" in breast radiation therapy in North America, speaks highly of the acceptance of AccuBoost. The main highlights of this publication are:

Practicality: The treatment can be easily implemented in a variety of community based and academic institutions.

Feasibility: The treatment is reliable, reproducible and well tolerated.

Patient age: Mean patient age was 61 with a range from 32 to 88.

Schedule: 48%, 48% and 4% of patients received the treatment prior to, during and post WBI, respectively.

Clinical Investigation

A Multi-Institutional Study of Feasibility, Implementation, and Early Clinical Results with Noninvasive Breast Brachytherapy for Tumor Bed Boost

Subarna Hamid, M.D., Ph.D.,*[†] Kathy Rocchio, M.S.,[†] Douglas Arthur, M.D.,[‡] Robyn Vera, M.D.,[‡] Sandra Sha, M.D.,[§] Michele Jolly, M.S.,[§] Sean Cavanaugh, M.D.,[¶] Eric Wooten, B.S.,[¶] Rashmi Benda, M.D.,^{||} Brad Greenfield, B.S.,^{||} Bradley Prestidge, M.D.,** Scot Ackerman, M.D.,^{††} Robert Kuske, M.D.,^{‡‡} Coral Quiet, M.D.,^{‡‡} Margaret Snyder, R.N., CCRP,^{‡‡} and David E. Wazer, M.D.*[†]

*Department of Radiation Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA; [†]Department of Radiation Oncology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI; [‡]Department of Radiation Oncology, Virginia Commonwealth University, Richmond, VA; [§]Central Florida Cancer Institute, Davenport, FL; [¶]Atlanta Oncology Associates, Hawkinsville, GA; ^{||}Department of Radiation Oncology, Boca Raton Community Hospital, Boca Raton, FL; ^{**}Texas Cancer Clinic, San Antonio, TX; ^{††}First Coast Oncology, Jacksonville, FL; and ^{‡‡}Arizona Breast Cancer Specialists, Phoenix, AZ

Received Apr 3, 2011, and in revised form Sep 29, 2011. Accepted for publication Oct 4, 2011

Discomfort: Overall 14% of patients complained about discomfort, among this group the discomfort was lowest at 12% when boost was given prior to WBI.

Procedure time: Overall patient treatment time was 17 +/- 7 minutes.

Toxicity & Cosmetic results: Much less (acute) skin toxicity: 0% grade 3, much lower grade 2, essentially all grade 1 & 0

“Patient data registry” (cont.)


The newly published patient data registry has been recently updated to include additional patients that bring the total to 264. The latest results for the registry were the subject of an oral presentation at the recent World Congress/ESTRO in Barcelona. The lead author, Dr. Subarna Hamid, presented longer term observations and the more mature data. Among the findings are that there is no ipsilateral breast failure that has been reported. There was one (1) case of death reported in a patient with diffuse skeletal metastasis, 2 years after completing breast radiation.

The new data concentrates on toxicity and cosmesis following the completion of radiation therapy. It grades the patients according to the Common Toxicity Criteria (CTC, v3.0) and the Harvard scale. The result for the toxicity and cosmesis are presented in the Tables on the right.

The author concludes that:


- AccuBoost is a safe method of delivering high dose rate photon irradiation under real time image guidance. The procedure for tumor bed boost is well tolerated.
- Based on early clinical results, AccuBoost treated patients experience low toxicity and excellent cosmetic outcome.

Toxicity improves with time



Interval since completion of NIBB

Excellent cosmetic results also improves with time



Interval since completion of Radiation (months)



Advanced Radiation Therapy
One Industrial Way
Tyngsboro, MA 01879

Phone: 978-649-0007
Fax: 978-649-0077
E-Mail: info@AccuBoost.com

Advanced Radiation Therapy
One Industrial Way
Tyngsboro, MA 01879

